<?xml version="1.0" encoding="UTF-8"?>
<ref id="hep41482-bib-0005">
 <label>5</label>
 <mixed-citation publication-type="journal" id="hep41482-cit-0005">
  <string-name>
   <surname>Zeuzem</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Foster</surname>
   <given-names>GR</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Asatryan</surname>
   <given-names>A</given-names>
  </string-name>, 
  <string-name>
   <surname>Gane</surname>
   <given-names>E</given-names>
  </string-name>, 
  <string-name>
   <surname>Feld</surname>
   <given-names>JJ</given-names>
  </string-name>, et al. 
  <article-title>Glecaprevir‐pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</article-title>. 
  <source xml:lang="en">N Engl J Med</source>
  <year>2018</year>;
  <volume>378</volume>:
  <fpage>354</fpage>‐
  <lpage>369</lpage>.
  <pub-id pub-id-type="pmid">29365309</pub-id>
 </mixed-citation>
</ref>
